Trial Profile
Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 May 2018
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors Baxter Healthcare Corporation
- 04 Nov 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 08 Dec 2008 Status changed from not yet recruiting to recruiting.
- 22 Nov 2008 New trial record.